Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Journal of the Neurological Sciences
|
June 1, 2025
Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study
Kimiaki Utsugisawa, Masayuki Masuda, Babak Boroojerdi, et al.
Drug Safety
|
May 23, 2020
A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data
Christen M Gray, Fiona Grimson, Deborah Layton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 10, 2021
Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials
Dony Patel, Fiona Grimson, Elena Mihaylova, et al.
Journal of Avian Medicine and Surgery
|
January 16, 2016
Comparison of Hematologic and Biochemical Test Results in Blood Samples Obtained by Jugular Venipuncture Versus Nail Clip in Moluccan Cockatoos (Cacatua moluccensis)
Tracy D Bennett, Daniel V Lejnieks, Hoyt Koepke, et al.
Journal of Neurology
|
November 8, 2025
Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study
Carolina Barnett-Tapia, Elena Cortés Vicente, Robert M Pascuzzi, et al.
Journal of Neurology
|
June 12, 2025
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis
Channa Hewamadduma, Miriam Freimer, Angela Genge, et al.
Neurology
|
February 20, 2025
Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001)
Ali A Habib, Henry J Kaminski, Julian Grosskreutz, et al.
European Journal of Neurology
|
August 4, 2025
Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO
Henry J Kaminski, Carlo Antozzi, Ali A Habib, et al.
Pharmacoepidemiology and Drug Safety
|
April 29, 2024
Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls
Christen Gray, Eleanor Ralphs, Matthew P Fox, et al.
European Journal of Cancer Care
|
July 21, 2021
Small cell lung cancer treatment and survival in Portugal: A retrospective analysis from the I-O Optimise initiative
Marta Soares, Luís Antunes, Patrícia Redondo, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Journal of the Neurological Sciences
|
June 1, 2025
Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study
Kimiaki Utsugisawa, Masayuki Masuda, Babak Boroojerdi, et al.
Drug Safety
|
May 23, 2020
A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data
Christen M Gray, Fiona Grimson, Deborah Layton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 10, 2021
Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials
Dony Patel, Fiona Grimson, Elena Mihaylova, et al.
Journal of Avian Medicine and Surgery
|
January 16, 2016
Comparison of Hematologic and Biochemical Test Results in Blood Samples Obtained by Jugular Venipuncture Versus Nail Clip in Moluccan Cockatoos (Cacatua moluccensis)
Tracy D Bennett, Daniel V Lejnieks, Hoyt Koepke, et al.
Journal of Neurology
|
November 8, 2025
Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study
Carolina Barnett-Tapia, Elena Cortés Vicente, Robert M Pascuzzi, et al.
Journal of Neurology
|
June 12, 2025
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis
Channa Hewamadduma, Miriam Freimer, Angela Genge, et al.
Neurology
|
February 20, 2025
Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001)
Ali A Habib, Henry J Kaminski, Julian Grosskreutz, et al.
European Journal of Neurology
|
August 4, 2025
Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO
Henry J Kaminski, Carlo Antozzi, Ali A Habib, et al.
Pharmacoepidemiology and Drug Safety
|
April 29, 2024
Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls
Christen Gray, Eleanor Ralphs, Matthew P Fox, et al.
European Journal of Cancer Care
|
July 21, 2021
Small cell lung cancer treatment and survival in Portugal: A retrospective analysis from the I-O Optimise initiative
Marta Soares, Luís Antunes, Patrícia Redondo, et al.
Page
of 2